Insider plans sale of 7,000 Twist Bioscience shares

Adam Laponis filed a Form 144 indicating an intent to sell up to 7,000 shares of Twist Bioscience common stock.

Rhea-AI Filing Summary

Adam Laponis filed a Form 144 indicating an intent to sell up to 7,000 shares of Twist Bioscience common stock. The planned sale through Fidelity Brokerage Services on NASDAQ has an aggregate market value of 350000.00. Twist Bioscience had 61,311,704 common shares outstanding.

The shares to be sold were acquired through restricted stock vesting from the issuer on 10/01/2025, 10/08/2025, and 10/29/2025, totaling 6,, , , , , 614, 2,170, and 4,216 shares as compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Adam Laponis’s Form 144 filing mean for Twist Bioscience (TWST)?

The filing shows Adam Laponis plans to sell up to 7,000 Twist Bioscience common shares. These shares have an aggregate market value of $350,000 and will be sold through Fidelity Brokerage Services on NASDAQ, subject to Rule 144 conditions and market execution.

How many Twist Bioscience (TWST) shares does Adam Laponis plan to sell under this Form 144?

Adam Laponis intends to sell up to 7,000 common shares of Twist Bioscience. The filing lists an aggregate market value of $350,000 for this block, with the transaction routed through Fidelity Brokerage Services on NASDAQ, using Rule 144 resale procedures.

When did Adam Laponis acquire the Twist Bioscience (TWST) shares covered by this Form 144?

The shares were acquired via restricted stock vesting from the issuer on October 1, 2025, October 8, 2025, and October 29, 2025. The respective vested amounts were 614, 2,170, and 4,216 common shares, all characterized as compensation rather than cash purchases.

What recent Twist Bioscience (TWST) share sales has Adam Laponis reported in the last three months?

The filing lists three recent sales of Twist Bioscience common shares by Adam Laponis: 887 shares on November 21, 2025 for $23,508.60, 2,738 shares on January 9, 2026 for $96,544.34, and 3,000 shares on January 13, 2026 for $120,000.00 in gross proceeds.

How many Twist Bioscience (TWST) shares are outstanding according to this Form 144?

The Form 144 states that 61,311,704 Twist Bioscience common shares are outstanding. This figure provides a baseline context for the planned 7,000-share sale, illustrating the relative size of the proposed transaction versus the total share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 01:07 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001827198
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Twist Bioscience Corp
SEC File Number	001-38720
Address of Issuer	681 GATEWAY BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	800-719-0671
Name of Person for Whose Account the Securities are To Be Sold	Laponis Adam
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	7000	350000.00	61311704	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Restricted Stock Vesting	Issuer			614	10/01/2025	Compensation
Common	10/08/2025	Restricted Stock Vesting	Issuer			2170	10/08/2025	Compensation
Common	10/29/2025	Restricted Stock Vesting	Issuer			4216	10/29/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Adam Laponis 681 Gateway Blvd South San Francisco CA 94080	Common	11/21/2025	887	23508.60
Adam Laponis 681 Gateway Blvd South San Francisco CA 94080	Common	01/09/2026	2738	96544.34
Adam Laponis 681 Gateway Blvd South San Francisco CA 94080	Common	01/13/2026	3000	120000.00

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Adam Laponis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)